AstraZeneca airs "consuming" consumer for Seroquel XR bipolar depression

Share this article:
AstraZeneca airs "consuming" consumer for Seroquel XR bipolar depression
AstraZeneca airs "consuming" consumer for Seroquel XR bipolar depression
AstraZeneca launched the first consumer TV and print ads for Seroquel XR for bipolar depression, playing on the all-consuming way in which patients experience the disease.

The ads, by Saatchi & Saatchi Wellness, feature the tagline “Bipolar depression doesn't just affect you – it can consume you,” along with visuals depicting sufferers fading into backgrounds like chameleons. The messaging is based on an emotional consumer insight, AstraZeneca said, noting that when symptomatic, people with bipolar disorder may experience depressive symptoms more than three times longer than manic symptoms, interfering with daily activities.

A 90-second TV ad will run regionally on network, syndication and cable TV for the remainder of the year, then go national in 2010. Print ads are running in national publications.

In addition, the brand is running a “robust” digital effort including display media and search engine marketing, along with banners on lifestyle sites, health portals and niche mental health sites like HealthyPlace, RealMentalHealth and the Glispa Network of Menatl Health. Homepage “roadblocks” are running through December on the sites of Yahoo, Fox News, The New York Times and ABC. Digitas Health handles digital assignments on the brand.

The sustained release formula of the drug won FDA approval for the treatment of bipolar depression and bipolar mania in October, 2008. The atypical antipsychotic is also indicated for schizophrenia and major depressive disorder.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...